The Japan Patent Office has granted Can-Fite BioPharma (NYSE MKT:CANF) (TASE:CFBI) a patent for its lead drug candidate, CF101, for the reduction of intraocular pressure (IOP). CF101 is an A3 adenosine receptor (A3AR)...
Closely-held Soricimed Biopharma has reached its target enrollment and treatment duration in a Phase 1 trial to evaluate the safety and tolerability of SOR-C13 in patients with solid tumor cancers who have failed other...
Closely-held BioSight of Israel reported positive interim results in an abstract at the ASH meeting last week from a Phase 1/2a clinical study of Astarabine in leukemia patients. The aim of the study was to evaluate the...
The FDA’s Psychopharmacologic Drugs Advisory Committee has scheduled a meeting on Jan. 12 to review the NDA for Titan Pharmaceuticals’ (NASDAQ: TTNP) Probuphine for the maintenance treatment of opioid addiction. The FDA...
Can-Fite BioPharma’s (NYSE MKT:CANF; TASE:CFBI) subsidiary, OphthaliX (OTCQB:OPLI), has completed enrollment of 88 patients in its Phase 2 trial of CF101, an oral treatment for glaucoma. The trial is being conducted in...
Closely-held Ciclofilin Pharmaceuticals has assembled a world-class team of scientists and clinicians for its scientific advisory board (SAB) to guide the company through its drug development program for its lead drug...
BioLight Life Sciences Investments’ (OTCQX:BLGTY; TASE:BOLT) cancer diagnostics subsidiary, Micromedic Technologies (TASE:MCTC), has entered into a collaboration agreement with Axella Research to advance the clinical...
Oramed Pharmaceuticals (NASDAQ:ORMP) has signed definitive licensing and investment agreements valued at up to $50-million with Hefei Tianhui Incubator of Technologies (HTIT) for exclusive rights to market Oramed’s oral...
BioLight Life Sciences Investments (OTCQX:BLGTY; TASE:BOLT) and two Asia-based venture capital firms have entered into a joint financing agreement for a direct equity investment in BioLight’s IOPtima subsidiary via a...
Kitov Pharmaceuticals Holdings (NASDAQ:KTOV) has priced an initial public offering of 3,158,900 American Depository Shares (ADS) and warrants to purchase up to 3,158,900 ADS for gross proceeds expected to be...
Can-Fite BioPharma’s (NYSE MKT:CANF; TASE:CFBI) drug candidate, CF102, which is currently in Phase 2 trials for hepatocellular carcinoma (HCC), the most common form of liver cancer, will be expanded into the treatment...
Closely-held B-TEMIA has initiated a multi-center pivotal trial aimed at demonstrating the superior clinical benefits and safety for home use of its powered-assistive Dermoskeleton technology, called Keeogo, for...
Viking Therapeutics (NASDAQ:VKTX) and the Kennedy Krieger Institute announced a sponsored research collaboration focused on evaluating Viking’s thyroid beta agonists for the treatment of X-linked adrenoleukodystrophy (X...
Viking Therapeutics (NASDAQ:VKTX) has submitted an IND application to the FDA to conduct a Phase 2 study of VK2809 in patients with hypercholesterolemia and fatty liver disease. Viking expects to initiate the Phase 2...
Titan Pharmaceuticals (NASDAQ:TTNP) has added an implantable triiodothyronine (T3) product for the treatment of hypothyroidism to its product development pipeline. Hypothyroidism affects about 15 million Americans...
Dipexium Pharmaceuticals’ (NASDAQ:DPRX) OneStep Phase 3 placebo-controlled, pivotal clinical trials of Locilex in the treatment of patients with mild infections of diabetic foot ulcers are approximately 62% enrolled...
Avivagen (TSX-V:VIV) and COFCO Nutrition and Health Research Institute (NHRI), an affiliate of the Chinese government’s COFCO Group, have agreed to conduct a trial of OxC-beta Livestock as a feed additive for swine. The...
Avivagen (TSX-V:VIV) has signed an agreement with the Bloom Burton Healthcare Lending Trust for a secured drawdown credit facility of up to $1.8-million. The facility will advance Avivagen’s plans for commercializing...
Transition Therapeutics (NASDAQ:TTHI; TSX:TTH) has entered an agreement for an investigator-led clinical study of drug candidate, TT701, with Brigham and Women’s Hospital (BWH). Transition will support the Phase 2 study...
Novadaq Technologies (NASDAQ:NVDQ; TSX:NDQ) reported revenue of $17-million for the third quarter this year, an increase of 40% from $12.1-million a year ago. Product sales increased by $5.2-million, or 47%, primarily...
Avivagen (TSX-V:VIV) has agreed with the National Institute of Animal Sciences for Vietnam (NIAS) to conduct a further trial of OxC-beta livestock as a feed additive for swine. Earlier this year, Avivagen and NIAS...
Can-Fite BioPharma (NYSE MKT:CANF; TASE:CFBI) has reported new findings for its CF602 drug candidate showing a defined mechanism of action in erectile dysfunction similar to sildenafil (Viagra) in a rat model of...